Orders from 190 AUD Free delivery from 395 AUD Ready for pickup dead drop: collect in 5 min

Substances · Cathinone derivatives

α-PHP

C16H23NO CAS 13415-86-6 Analytical reference material — not for human consumption
Preferred name
α-PHP
IUPAC name
1-phenyl-2-pyrrolidin-1-ylhexan-1-one
Parent CAS number (reference)
13415-86-6
Molecular formula
C16H23NO
Molecular weight
245.36 g/mol
InChIKey
KYIJLDDXQWBNGX-UHFFFAOYSA-N
PubChem
CID 102107923
Source
PubChem
Verified synonyms & catalog abbreviations
alpha-PHP a-PHP aPHP alpha-pyrrolidinohexiophenone PV-7

Matching Listings in This Store's Catalog

Verified Neurochemical & Toxicological Intelligence

alpha-PHP (alpha-Pyrrolidinohexiophenone / PV-7)

Potent Stimulant (Selective NDRI + M1/M2 Muscarinic Antagonist) Substituted cathinone / Pyrrolidinophenone (straight-chain hexanophenone)
Verified PubChem & CAS Identity C16H23NO · CAS 13415-86-6 · CID 102107923
Calibrated Physical Form Pure Crystalline / Analytical Powder (≥98%)
≥98% Analytical Purity Verified 245.37 g/mol
Peer-Reviewed & Agency Citations 3 · verified sources

Receptor Telemetry & Mechanism of Action

DAT Dopaminergic Signaling Primary
NET Noradrenergic Signaling Active
SERT Serotonergic Signaling Variable

Straight-chain six-carbon homologue of alpha-PVP (and chain isomer of alpha-PiHP) acting as a potent norepinephrine-dopamine reuptake inhibitor with a DAT/SERT selectivity ratio > 1,000 (0.06 at DAT and 0.06 at NET vs. 245 at SERT in comparative pyrovalerone transporter assays). Uniquely among close siblings, alpha-PHP also antagonizes human M1 and M2 muscarinic acetylcholine receptors, intensifying xerostomia (dry mouth), tachycardia, urinary difficulty, and delirium risk at heavy exposures.

Biotransformation & Active Metabolites

Human urinary studies identify 11 Phase I and 5 Phase II metabolites dominated by dihydroxy-pyrrolidinyl-alpha-PHP (M5, 45.1%) and dihydro-alpha-PHP (M1, 25.5%). WHO 42nd ECDD highlights an extended half-life contributing to long-lasting psychotic symptoms; confirmed to cross the placenta.

Temporal Pharmacokinetics

Powerful, forced catecholaminergic stimulation with full-body mood-elevating tingling, narrow task fixation, topical mouth/nasal numbing, and a slightly less sharp initial rush than alpha-PVP paired with a longer wakefulness tail.

  1. Onset 2–20 minutes oral
  2. Peak Window 1–2.5 hours
  3. Total Window 2–8 hours oral
  4. Residual / Half-Life 1–48 hours of residual wakefulness, tachycardia, and potential long-lasting psychotic symptoms (extended half-life noted by WHO 42nd ECDD; exact numerical plasma t1/2 unverified).

Milligram potency matches alpha-PVP (common oral 10–25 mg; mucosal 10–20 mg; vaporized 6–15 mg), while residual stimulation can linger up to 48 hours. repeated exposure before residual levels clear stacks sudden blood-pressure surges ('exploding heart' sensation), intense vasoconstriction, tremors, and long-lasting paranoid psychosis.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
1–5 mg oral (mucosal: 2–4 mg; vaporized: 1–2 mg)
Cognitive & Sensory

Subtle mental sharpening, alertness, and reduced drowsiness.

Somatic & Autonomic

Mild pulse elevation and faint dry mouth.

Light
5–10 mg oral (PMC11051472 5–15 mg; mucosal: 4–10 mg; vaporized: 3–6 mg)
Cognitive & Sensory

Strong wakefulness, narrow task focus, talkativeness, and confident mood lift.

Somatic & Autonomic

Noticeable heart-rate increase, dry mouth, and appetite suppression.

Common Reference
10–25 mg oral (mucosal: 10–20 mg; vaporized: 6–15 mg)
Cognitive & Sensory

Intense mood-elevating body tingling, hyper-fixation on repetitive tasks, tactile enhancement, and strong urge to redose.

Somatic & Autonomic

Marked tachycardia, elevated blood pressure, strong dry mouth, sweating, jaw clenching, and local mucosal numbing.

Strong
25–40 mg oral (mucosal: 20–35 mg; vaporized: 15–25 mg)
Cognitive & Sensory

Forced restlessness, hand unsteadiness, nystagmus (blurry vibrating vision), anxiety, and paranoid hyper-vigilance.

Somatic & Autonomic

Severe peripheral vasoconstriction, sudden blood-pressure spikes, difficulty urinating, muscle spasms, and prolonged insomnia.

Heavy / Toxic Zone
40+ mg oral (mucosal: 35+ mg; vaporized: 25+ mg)
Cognitive & Sensory

Long-lasting paranoid psychosis, hallucinations, agitation, delirium, or somnolent unresponsiveness.

Somatic & Autonomic

Dangerous hypertension, cardiac arrest, hyperthermia, rhabdomyolysis, seizures, and intrauterine fetal asphyxia in pregnancy.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

MAOIs (phenelzine, tranylcypromine, moclobemide, harmala alkaloids)

Potent DAT/NET blockade combined with MAO inhibition causes fatal hypertensive crisis, stroke, and hyperthermia.

Other stimulants and 25x-NBOMe (Cocaine, alpha-PVP, alpha-PiHP, MDPHP, Hexen, NEP, MDMA)

Synergistic vasoconstriction, muscarinic-antagonist tachycardia, malignant hypertension, and cardiac arrest.

Tramadol and Opioids

Tramadol induces seizures; co-consumed opiates (detected in 60% of a 29-case clinical/forensic alpha-PHP series) cause severe poly-intoxication and respiratory arrest.

Elevated Hazard — Avoid

Anticholinergics / Antihistamines (diphenhydramine, atropine, scopolamine)

Compounds alpha-PHP's intrinsic M1/M2 muscarinic antagonism, worsening tachycardia, hyperthermia, urinary retention, and delirium.

Alcohol, Benzodiazepines (co-detected in 35% of forensic cases), and GHB/GBL

Masks depressant intoxication, accelerates severe dehydration, and increases collapse risk; strictly contraindicated in pregnancy.

Caution / Receptor Attenuation

Cannabis

Frequently precipitates acute paranoia, racing pulse, and hallucinations during alpha-PHP's long offset.

Caffeine

Intensifies tremors, palpitations, and restless leg symptoms.

Structural Isomer & Sibling Comparison

alpha-PHP (PV-7) is the straight-chain 6-carbon homologue of alpha-PVP and positional chain isomer of alpha-PiHP. PsychonautWiki notes alpha-PHP is slightly less aggressively stimulating at onset than alpha-PVP while sharing identical oral milligram brackets (10–25 mg common), lasting longer (2–8 h vs. 2–6 h) with a longer residual tail (up to 48 h) and extra M1/M2 muscarinic dry-mouth/urinary effects. Compared to alpha-PiHP, alpha-PHP is longer-acting (2–8 h vs. 2–5 h).

Physicochemical Stability & Storage

Form: Transparent to whitish or pale yellowish crystals, or beige/off-white crystalline powder (HCl salt) with a bitter taste and topical mucosal numbing. · Soluble in water/PBS, ethanol, methanol, DMF, and DMSO.

Store sealed in an airtight, light-protected container in a cool, dry place.

Cross-Tolerance & Dependence Profile

Very high abuse and psychological dependence liability; rapid tolerance within a single session and full cross-tolerance with alpha-PVP, alpha-PiHP, MDPHP, Hexen, NEP, and cocaine (3–7 days to halve, 1–2 weeks to baseline).

Comprehensive Analytical & Toxicological Monograph

alpha-PHP (alpha-pyrrolidinohexiophenone / PV-7; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one; freebase CAS 13415-86-6, hydrochloride CAS 13415-59-3, PubChem CID 102107923) is a six-carbon straight-chain pyrrolidinophenone cathinone queued in weekly synthesis slot #14 as pure analytical crystals or crystalline powder (C16H23NO, 245.37 g/mol). Extending alpha-PVP's alkyl chain by one carbon preserves high-potency norepinephrine and dopamine reuptake inhibition (DAT/SERT selectivity ratio > 1,000) while adding antagonist activity at human M1 and M2 muscarinic receptors—contributing to pronounced dry mouth, tachycardia, and urinary difficulty. Human urinary toxicology identifies dihydroxy-pyrrolidinyl-alpha-PHP (45.1%) and dihydro-alpha-PHP (25.5%) as dominant metabolites, while the WHO 42nd ECDD notes an extended half-life linked to long-lasting psychotic symptoms. Precise low-milligram measurement is mandatory: oral threshold activity starts at 1–5 mg, light focus and energy span 5–10 mg, common intense stimulation sits at 10–25 mg (mucosal 10–20 mg; vaporized 6–15 mg), strong forced stimulation with nystagmus, tremors, and severe vasoconstriction appears at 25–40 mg, and heavy overdose danger begins above 40 mg. Oral primary effects last 2–8 hours (peaking at 1–2.5 hours), while residual wakefulness can persist up to 48 hours, making repeated exposure binges prone to severe blood-pressure spikes, rhabdomyolysis, and delirium. Compared to alpha-PVP, alpha-PHP is slightly less harsh initially yet lingers longer; compared to branched isomer alpha-PiHP, it has a longer duration (2–8 h vs. 2–5 h). Never mix alpha-PHP with MAOIs, other stimulants, anticholinergics, tramadol, opioids, or 25x-NBOMe, and strictly avoid in pregnancy.

Chemical Architecture & Structural Profile

α-PHP (1-phenyl-2-pyrrolidin-1-ylhexan-1-one) is a reference compound belonging to the Cathinone derivatives class, characterized by the molecular formula C16H23NO and a molar mass of 245.36 g/mol. The parent molecule is indexed under CAS registry number 13415-86-6 and in the NCBI PubChem database as CID 102107923 (Standard InChIKey: KYIJLDDXQWBNGX-UHFFFAOYSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), α-PHP is indexed within the Cathinone, Substituted cathinones, Substituted pyrrolidines structural group. Toxicological notes (PsychonautWiki): exact toxic threshold is unknown. Dependence liability (PsychonautWiki): highly addictive with a high potential for abuse. Documented cross-tolerance class: dopamine, stimulant. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations

Documented Contraindications & Interactions

High-risk / Dangerous combinations

Unsafe combinations (elevated hazard)

Uncertain combinations (caution advised)